BioPharmSignal logoBioPharmSignal

Biotech News

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

Lineage Cell Therapeutics (LCTX)Lineage Cell TherapeuticsEarnings

CARLSBAD, Calif. --(BUSINESS WIRE)--Nov. 5, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2026

Related news

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

OCGNOcugen2026-10-22 11:00 EST

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

LENZLenz Therapeutics Inc2026-10-28 20:30 EST

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

LENZLenz Therapeutics Inc2026-10-22 12:00 EST

LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

IRIXIRIDEX2026-11-03 21:05 EST

Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026

OCULOcular Therapeutix2026-11-02 12:00 EST

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

TARSTarsus Pharmaceuticals2026-10-29 20:30 EST

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

View all latest news

Lineage Cell Therapeutics

Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic...

Recent company news

LCTXLineage Cell Therapeutics2026-11-05 13:00 EST

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

LCTXLineage Cell Therapeutics2026-10-29 12:00 EST

Lineage Provides Update on ReSonance® Program for Hearing Loss

LCTXLineage Cell Therapeutics2026-09-08 12:00 EST

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Stock data

Close
0.98 USD
Market cap
301.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States